TESTING (2017) — Trial Summary
TESTING (2017): Randomized, double-blind, placebo-controlled trial of oral methylprednisolone versus placebo in adults with IgA nephropathy and proteinuria ≥1 g/day despite optimized RAS blockade (NCT01560052). Primary composite: 40% decline in eGFR, end-stage kidney disease, or death due to kidney
References
- Lv J, Zhang H, Wong MG, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017;318(5):432-442.